Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis - Author's reply.
作者信息
Kashour Tarek, Tleyjeh Imad M
机构信息
Department of Cardiac Sciences, King Fahad Cardiac Center, King Saud University Medical City, Riyadh, Saudi Arabia.
Infectious Diseases Section, Department of Medical Specialties King Fahad Medical City, Riyadh, Saudi Arabia; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; Division of Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, USA; Division of Epidemiology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
出版信息
Clin Microbiol Infect. 2021 Aug;27(8):1177-1178. doi: 10.1016/j.cmi.2021.02.024. Epub 2021 Mar 8.
Abstract
摘要
相似文献
1
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis - Author's reply.托珠单抗治疗新冠肺炎患者的疗效和安全性：一项实时系统评价与荟萃分析——作者回复
Clin Microbiol Infect. 2021 Aug;27(8):1177-1178. doi: 10.1016/j.cmi.2021.02.024. Epub 2021 Mar 8.
2
Re: 'Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis' by Tleyjeh et al.
Clin Microbiol Infect. 2021 Aug;27(8):1175-1176. doi: 10.1016/j.cmi.2021.01.025. Epub 2021 Feb 5.
3
Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis.托珠单抗治疗住院COVID-19患者的疗效和安全性：一项系统评价和荟萃分析。
J Infect. 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.11.013. Epub 2021 Nov 20.
4
'Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM' - Author's reply.“在炎症标志物升高的住院COVID-19患者中早期使用托珠单抗；COVIDSTORM”——作者回复
Clin Microbiol Infect. 2022 Nov;28(11):1520-1521. doi: 10.1016/j.cmi.2022.06.028. Epub 2022 Jul 4.
5
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.托珠单抗治疗 COVID-19 患者的疗效和安全性：一项实时系统评价和荟萃分析，首次更新。
Clin Microbiol Infect. 2021 Aug;27(8):1076-1082. doi: 10.1016/j.cmi.2021.04.019. Epub 2021 Apr 27.
6
Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.托珠单抗治疗与 COVID-19 患者临床结局的相关性：系统评价和荟萃分析。
Aging (Albany NY). 2022 Jan 17;14(2):557-571. doi: 10.18632/aging.203834.
7
Safety concerns regarding concomitant use of tocilizumab and glucocorticoids in COVID-19 patients.关于在新冠病毒肺炎患者中同时使用托珠单抗和糖皮质激素的安全性问题。
Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30025-30026. doi: 10.1073/pnas.2009253117. Epub 2020 Nov 12.
8
Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis.托珠单抗、沙利鲁单抗和阿那白滞素治疗 COVID-19 患者的疗效和二次感染风险：系统评价和荟萃分析。
Rev Med Virol. 2022 May;32(3):e2295. doi: 10.1002/rmv.2295. Epub 2021 Sep 24.
9
Tocilizumab in Treatment for Patients With COVID-19-Reply.托珠单抗治疗新型冠状病毒肺炎患者的回复
JAMA Intern Med. 2021 Jul 1;181(7):1019-1020. doi: 10.1001/jamainternmed.2021.0404.
10
Tocilizumab in Treatment for Patients With COVID-19-Reply.托珠单抗用于治疗新型冠状病毒肺炎患者的回复
JAMA Intern Med. 2021 Jul 1;181(7):1020-1021. doi: 10.1001/jamainternmed.2021.0407.
引用本文的文献
1
Therapeutic Impact of Tocilizumab in the Setting of Severe COVID-19; an Updated and Comprehensive Review on Current Evidence.托珠单抗在重症新型冠状病毒肺炎中的治疗作用；对当前证据的最新综合综述
Arch Acad Emerg Med. 2024 May 9;12(1):e47. doi: 10.22037/aaem.v12i1.2217. eCollection 2024.
本文引用的文献
1
Mutation Rates and Selection on Synonymous Mutations in SARS-CoV-2.SARS-CoV-2 中同义突变的突变率和选择。
Genome Biol Evol. 2021 May 7;13(5). doi: 10.1093/gbe/evab087.
2
Re: 'Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis' by Tleyjeh et al.
Clin Microbiol Infect. 2021 Aug;27(8):1175-1176. doi: 10.1016/j.cmi.2021.01.025. Epub 2021 Feb 5.
3
SARS-CoV-2 evolution during treatment of chronic infection.慢性感染治疗过程中 SARS-CoV-2 的进化。
Nature. 2021 Apr;592(7853):277-282. doi: 10.1038/s41586-021-03291-y. Epub 2021 Feb 5.
4
Temporal increase in D614G mutation of SARS-CoV-2 in the Middle East and North Africa.中东和北非地区新冠病毒D614G突变的时间性增加。
Heliyon. 2021 Jan;7(1):e06035. doi: 10.1016/j.heliyon.2021.e06035. Epub 2021 Jan 20.
5
Evolution and genetic diversity of SARS-CoV-2 in Africa using whole genome sequences.利用全基因组序列分析非洲地区 SARS-CoV-2 的进化和遗传多样性。
Int J Infect Dis. 2021 Feb;103:282-287. doi: 10.1016/j.ijid.2020.11.190. Epub 2020 Nov 28.
6
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.托珠单抗治疗 COVID-19 患者的疗效和安全性：一项实时系统评价和荟萃分析。
Clin Microbiol Infect. 2021 Feb;27(2):215-227. doi: 10.1016/j.cmi.2020.10.036. Epub 2020 Nov 5.
7
Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study.托珠单抗阻断白细胞介素 6 对 COVID-19 患者 SARS-CoV-2 病毒动力学和抗体反应的影响：一项前瞻性队列研究。
EBioMedicine. 2020 Oct;60:102999. doi: 10.1016/j.ebiom.2020.102999. Epub 2020 Sep 16.
8
Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission.系统评价与荟萃分析：SARS-CoV-2 粪便检测与粪口传播的可能性。
Aliment Pharmacol Ther. 2020 Oct;52(8):1276-1288. doi: 10.1111/apt.16036. Epub 2020 Aug 27.
9
Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm.单细胞分析两名重症 COVID-19 患者揭示了与单核细胞相关且对托珠单抗有反应的细胞因子风暴。
Nat Commun. 2020 Aug 6;11(1):3924. doi: 10.1038/s41467-020-17834-w.
10
Mutation Patterns of Human SARS-CoV-2 and Bat RaTG13 Coronavirus Genomes Are Strongly Biased Towards C>U Transitions, Indicating Rapid Evolution in Their Hosts.人类 SARS-CoV-2 和蝙蝠 RaTG13 冠状病毒基因组的突变模式强烈偏向 C>U 转换，表明其宿主中存在快速进化。
Genes (Basel). 2020 Jul 7;11(7):761. doi: 10.3390/genes11070761.
Zotero 插件